No Data
Shandong Jincheng Pharmaceutical Group's Antibiotic Gets Chinese Drug Regulator's Approval
shandong jincheng pharmaceutical group (300233.SZ): Cefamandole nafate dry suspension passed consistency evaluation
shandong jincheng pharmaceutical group (300233.SZ) announced that its wholly-owned subsidiary shanghai jinchengsuzhi pharmaceutical co., ltd. (referred to as ...
Solid Earnings May Not Tell The Whole Story For Shandong Jincheng Pharmaceutical Group (SZSE:300233)
Jincheng Pharmaceutical: Report for the third quarter of 2024
Shandong Jincheng Pharmaceutical Group (300233.SZ) released its performance for the first three quarters, with a net income of 0.151 billion yuan, an increase of 14.02%.
Shandong Jincheng Pharmaceutical Group (300233.SZ) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 2...
Shandong Jincheng Pharmaceutical Group Co., Ltd (SZSE:300233) Held Back By Insufficient Growth Even After Shares Climb 26%
Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatioNo Data
No Data
